Clopidogrel (Plavix)

descriptionPublicationkeyboard_double_arrow_right Article 01 Dec 2011 English Publisher:American Society of Neuroradiology (ASNR)Journal:American Journal of Neuroradiology, volume 32, pages 2,002-2,004 (issn: 0195-6108, eissn: 1936-959X,

Copyright policy )

Authors: J, Comin; D, Kallmes;

doi: 10.3174/ajnr.a2913

pmid: 22135129

pmc: PMC7964406

Clopidogrel (Plavix)

- Summary
- Subjects
- Metrics

Abstract

Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

Related Organizations

Mayo Clinic
United States
St Vincent's Hospital
Australia

Keywords

Stroke, Ticlopidine, Dose-Response Relationship, Drug, Humans, Hemorrhage, Platelet Aggregation Inhibitors, Clopidogrel

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	12
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average